Health Affairs, 25, no. 5 (2006): 1353-1362 doi: 10.1377/hlthaff.25.5.1353 © 2006 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Figures Only Full Text (HTML) Reprint (PDF) Appendix Exhibits Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Danzon, P. M. Articles by Furukawa, M. F. Search for Related Content PubMed PubMed Citation Articles by Danzon, P. M. Articles by Furukawa, M. F. Related Collections Insurance Market Access To Care Business Of Health Consumer Issues Insurance Coverage International Issues Pharmaceuticals Research And Technology Health Spending

Health Tracking

MARKETWATCH

Prices And Availability Of Biopharmaceuticals: An International Comparison

This paper presents new evidence on availability, use, and prices of biopharmaceuticals in five major European Union (EU) markets, Canada, Australia, Japan, and Mexico, relative to the United States. Our data set from IMS Health includes all product sales in 2005. Per capita spending on biopharmaceuticals was at least twice as high in the United States as in the other countries. This difference reflects primarily greater availability and use of new, relatively high-price molecules and formulations. Prices for identical formulations are not higher on average in the United States. The broader price indexes, which do not control formulation, are also not higher in the United States, after adjusting for income.

                      What's this?

This article has been cited by other articles:

				R. Lopert and S. Rosenbaum What Is Fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the United States and Australia J. Law Med. Ethics, December 1, 2007; 35(4): 643 - 656. [PDF]

				R. Lopert and M. Moon Toward A Rational, Value-Based Drug Benefit For Medicare Health Aff., November 1, 2007; 26(6): 1666 - 1673. [Abstract] [Full Text] [PDF]